Gilead Sciences, Inc. (NASDAQ:GILD) is Crossmark Global Holdings Inc.'s 8th Largest Position

Crossmark Global Holdings Inc. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 552,584 shares of the biopharmaceutical company's stock after buying an additional 12,364 shares during the quarter. Gilead Sciences accounts for approximately 1.1% of Crossmark Global Holdings Inc.'s holdings, making the stock its 8th biggest holding. Crossmark Global Holdings Inc.'s holdings in Gilead Sciences were worth $61,917,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Callan Capital LLC lifted its holdings in Gilead Sciences by 12.3% in the 1st quarter. Callan Capital LLC now owns 3,436 shares of the biopharmaceutical company's stock worth $385,000 after buying an additional 377 shares in the last quarter. Capital Advisors Inc. OK acquired a new position in Gilead Sciences in the 1st quarter worth $233,000. Chilton Capital Management LLC lifted its holdings in Gilead Sciences by 125,738.5% in the 1st quarter. Chilton Capital Management LLC now owns 235,318 shares of the biopharmaceutical company's stock worth $26,367,000 after buying an additional 235,131 shares in the last quarter. Argentarii LLC lifted its holdings in Gilead Sciences by 3.0% in the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock worth $380,000 after buying an additional 99 shares in the last quarter. Finally, Jackson Wealth Management LLC acquired a new position in Gilead Sciences in the 1st quarter worth $461,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the sale, the chief executive officer directly owned 620,268 shares of the company's stock, valued at $68,489,992.56. This represents a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $275,425.00. Following the sale, the chief financial officer directly owned 165,110 shares of the company's stock, valued at approximately $18,190,168.70. This represents a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 58,500 shares of company stock worth $6,340,745 over the last three months. Corporate insiders own 0.27% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GILD. Morgan Stanley upped their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Oppenheimer cut their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Finally, Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and a consensus target price of $110.55.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock traded up $0.03 on Monday, hitting $111.78. The company had a trading volume of 6,955,665 shares, compared to its average volume of 7,703,268. The business has a 50-day simple moving average of $107.02 and a 200-day simple moving average of $104.11. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The company has a market cap of $139.05 billion, a PE ratio of 23.53, a PEG ratio of 0.72 and a beta of 0.29. Gilead Sciences, Inc. has a 52 week low of $66.34 and a 52 week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business's revenue was down .3% on a year-over-year basis. During the same period last year, the firm posted ($1.32) earnings per share. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.83%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.